Development of a new, sensitive immunoassay for measuring transforming growth factor beta 1 (TGF-␤1) is described and compared with four commercially available TGF-␤1 immunoassays. Preanalytical conditions were evaluated. The nonlinearity found in serum or plasma is due to masking of TGF-␤1 by binding proteins in blood. Mixing TGF-␤1 with latency-associated peptide or ␣ 2 -macroglobulin at physiological concentrations suppressed most of the TGF-␤1 signal. Plasma fibronectin showed no effect, even at concentrations exceeding its physiological range. Equilibrium concentrations computed from a model system confirmed the experimental results. Dilutional nonlinearity could be markedly reduced by an appropriately designed activation procedure that minimized the effects of reassociation between TGF-␤1 and its binding partners during restoration of a neutral pH. Plasma should be used for measuring TGF-␤1 in blood. Because serum TGF-␤1 is highly significantly correlated with the platelet count, probably most of the TGF-␤1 is released by platelet degranulation.
Development of a new, sensitive immunoassay for measuring transforming growth factor beta 1 (TGF-␤1) is described and compared with four commercially available TGF-␤1 immunoassays. Preanalytical conditions were evaluated. The nonlinearity found in serum or plasma is due to masking of TGF-␤1 by binding proteins in blood. Mixing TGF-␤1 with latency-associated peptide or ␣ 2 -macroglobulin at physiological concentrations suppressed most of the TGF-␤1 signal. Plasma fibronectin showed no effect, even at concentrations exceeding its physiological range. Equilibrium concentrations computed from a model system confirmed the experimental results. Dilutional nonlinearity could be markedly reduced by an appropriately designed activation procedure that minimized the effects of reassociation between TGF-␤1 and its binding partners during restoration of a neutral pH. Plasma should be used for measuring TGF-␤1 in blood. Because serum TGF-␤1 is highly significantly correlated with the platelet count, probably most of the TGF-␤1 is released by platelet degranulation.
Transforming growth factor-␤ (TGF-␤) 1 belongs to a family of dimeric 25-kDa polypeptides that are ubiquitously distributed in tissues and synthesized by many different cells [1, 2] . In mammalians, three isoforms are found: TGF-␤1, TGF-␤2, and TGF-␤3. All three are cytokines with multiple functions, e.g., regulation of cell proliferation and differentiation, promotion of wound healing, and suppression of the immune system. While many cells are able to synthesize TGF-␤, the most prominent sources within the body are bone matrix and the ␣-granules of platelets [2] . Cells secrete TGF-␤ in a biologically inactive, latent form bound to an amino-terminal propeptide called latency-associated peptide (LAP). Transient acidification is commonly used to activate this so-called small, latent TGF-␤ (LTGF-␤), i.e., to release TGF-␤ from its noncovalent association with LAP. Numerous other proteins, including proteoglycans, type IV collagen, fibronectin, and other components of the extracellular matrix have been reported to noncovalently bind TGF-␤ [3, 4] . In blood, TGF-␤ supposedly occurs associated mainly with ␣ 2 -macroglobulin (␣2M) [5, 6] . The determination of TGF-␤ in blood has been advocated for diagnosis of various diseases, e.g., cancer [7, 8] , immunological disorders [9] , and hematological [10] [11] [12] or fibrotic [13] diseases.
Bioassays for assessment of functional TGF-␤ [14] and immunoassays for determination of TGF-␤ concentrations [15] [16] [17] [18] [19] have been described. However, review of the literature reveals different ranges given for the concentration of TGF-␤ in blood, and several different recommendations for preanalytical sample handling can be found. Given the abundance of TGF-␤ in platelets, some authors argue that serum measurements are not useful and that plasma concentrations have to be corrected by simultaneous measurement of markers of platelet degranulation [20] . In their opinion, direct measurement of TGF-␤ is not possible in plasma or serum by use of growth-inhibition assays, radioreceptor assays, or immunological assays because the dilution curves are not parallel to the calibration curves for these assays. An extraction procedure has been proposed to eliminate interfering substances. On the other hand, others report that serum and platelet-poor plasma concentrations are similar and that direct measurements of serum specimens thus "provide a reliable estimate of active and total TGF-␤ in plasma" [16] . The striking differences between the findings reported by different groups can at least in part be explained by different assay methodologies used. For example, the assays developed by Grainger et al. [16] , which are based on receptor binding of TGF-␤ and do not use an activation procedure, measure only a fraction of TGF-␤. These assays are not affected by platelet-derived TGF-␤, which is explained by the insensitivity of the assays to detect the large latent TGF-␤ complex, which contains the large TGF-␤-binding protein.
Although several commercial assay kits have been used recently to investigate the diagnostic efficacy of TGF-␤ blood concentrations, none of these assays has been evaluated by standardized method comparison methodology.
Here we describe a newly developed sandwich-type enzyme immunoassay for measuring TGF-␤1. Additionally, we compare this "in-house" assay with 4 commercially available immunological assays for determining TGF-␤1 in serum or plasma samples and define some important preanalytical conditions. The in-house assay is used as an (arbitrary) reference for the 4 commercial assays as well as for a detailed investigation of some fundamental aspects of measuring TGF-␤ in blood. In particular, to explain the nonlinearity encountered when measuring serial sample dilutions, we compare experimental data with the results of a simulation model. By using a modified acid-activation scheme, our newly developed assay can measure TGF-␤1 in blood samples without any significant influence from sample dilution.
Materials and Methods materials
Human serum and plasma were obtained from healthy blood donors or randomly collected from patients' samples submitted for routine analysis at our laboratory. A tourniquet was applied only when necessary and was removed after insertion of the 19-to 21-gauge needle for venipuncture. Serum samples were allowed to clot for 1-2 h at room temperature before centrifugation (20 min, 4000g, 4°C). Potassium EDTA or sodium citrate was used as anticoagulant for the plasma samples. Plasma was separated after centrifugation for 20 min at 4000g at 4°C. The platelet count of these samples was Ͻ4 ϫ 10 9 /L, as checked by an automated hematologic counter. Samples that were not analyzed immediately were stored at Ϫ80°C until assay. The procedures followed were in accordance with the ethical standards committee of the hospital.
Commercial immunoassay kits for the comparison determinations of TGF-␤1 were purchased: Predicta (Genzyme), Quantikine (R&D Systems, Minneapolis, MN), Amersham (Amersham International), and Promega (Promega). All assays were performed strictly as recommended by the manufacturers. A comprehensive description of the respective assay procedures has been compiled in Table 1 For calibration we used recombinant human TGF-␤1 at 667, 222, 74, 25, and 8.2 ng/L dissolved in assay buffer.
Acid activation of samples. Procedure 1: This procedure was designed according to the procedures typically used by the commercial assays and mainly was used for comparison purposes. After 50-fold dilution in assay buffer, 200-L plasma or serum samples were acidified with 20 L of 1 mol/L HCl for 15 min at room temperature and then neutralized with 1 volume of 1 mol/L NaOH. The neutralized samples were added to the microwells. This procedure produces a time lag of 10 to 15 min between neutralization of an individual sample and the start of its exposure to the solid-phase antibody. We confirmed that pH values of 2-3 (acidified) and 7-8 (neutralized) were obtained.
Procedure 2: Plasma or serum samples were diluted 50-fold in assay buffer and subsequently acidified by addition of 20 L of 1 mol/L HCl to 200 L of diluted sample. If desired, further dilution was performed in acidified assay buffer (assay buffer: 1 mol/L HCl, 10:1 by vol). After thorough mixing and 10 min of incubation at room temperature 11 volumes of the sample were neutralized with 1 volume of 1 mol/L NaOH. Care was taken that each sample was neutralized only 10 -15 s before addition to the coated microwell plate. We confirmed that by this procedure pH values of 2-3 (acidified) and 7-8 (neutralized) were obtained.
Assay procedure. The volume of calibrators, samples, and antibodies was each 100 L/well. Between incubation steps, the microwells were washed 3 times with washing solution by a mechanized washer. Assay plates were coated with chicken anti-TGF-␤1 diluted in coating buffer (2 mg/L) at 4°C overnight with shaking and were then blocked for 2 h at room temperature or overnight at 4°C with the assay buffer, 250 L/well.
Calibrators or activated test samples were incubated in the microwells in duplicate for 2 h at room temperature or overnight at 4°C with shaking. The secondary antibody was monoclonal panspecific mouse anti-TGF-␤1,2,3 (5 mg/L, 2 h at room temperature with shaking). Subsequently, biotinylated anti-mouse IgG antibody (0.5 mg/L in assay buffer) was added and incubated for 45 min at room temperature with shaking. Incubation for 30 min at room temperature with streptavidin-peroxidase (50 g/L) followed. Finally, BM blue POD substrate was added to each well. Color development was stopped after 4 -5 min by addition of 50 L of 1 mol/L H 2 SO 4 , and the absorbance was measured at 450 nm.
statistical and mathematical methods
The Astute statistical software package (DDU Software; University of Leeds, Leeds, UK) supplement for the Microsoft Excel spreadsheet package and the Statgraphics statistical package (STSC, Rockville, MD) were used for statistical calculations. Detection limits were calculated as 3SD Blank 
, where SD Blank is the SD of the assay blank, [S 0 ] is the concentration of the lowestconcentration calibrator, and A S0 and A Blank are the absorbances of the lowest calibrator and the blank, respectively. Comparisons between different assay kits were evaluated according to Passing and Bablok [21] . Spearman rank correlation was used throughout. The calibration curves of the assays were fitted through use of the four-parameter logistic function provided by the Milenia analyzer.
calculation of equilibrium concentrations
The simple iterative method of Perrin and Sayce [22, 23] is used for the computation of equilibrium concentrations. From the Law of Mass Action the equilibrium concentration c j of complex j in a system of M reactants A i in N chemical reactions with stability constants K j is given by: where the exponentials m ij are the stoichiometric coefficients of the reactants. The total concentration T i of reactant i is given by:
Combining the above expressions, we get:
Assuming that total concentrations and stability constants are known, the equilibrium concentrations of the components c A can be calculated iteratively:
The iteration starts with c A i ϭ c A i tot and continues until the differences between total concentrations computed and those given fall below a small threshold value. Convergence is typically reached after Ͻ50 iterations.
Results and Discussion in-house assay
The in-house TGF-␤1 assay had a practical measuring range of 8.2-667 ng/L, a detection limit of 1.9 ng/L, analytical recovery of 97% (n ϭ 3), intraassay imprecisions (CVs) of 2% (1000 ng/L), 3.5% (250 ng/L), and 8.5% (90 ng/L), and an interassay imprecision of 7.5%. A typical calibration curve and the corresponding precision profile are shown in Fig. 1 . Variation of the sample incubation period between 2 h and overnight had no significant effect on the sensitivity (detection limit) of the assay; for practical reasons, however, the latter was generally used. The TGF-␤1 assay did not show any crossreactivity with isoforms TGF-␤2 and TGF-␤3 at 100 g/L.
Only the activated form of TGF-␤ was detected by the assay: LTGF-␤1 at concentrations up to 400 g/L gave signals below the detection limit, whereas the expected concentrations were obtained after activation of the LTGF-␤1. Some additional analytical characteristics of the assay are shown in Table 1 , in comparison with those of the commercial assays.
The in-house assay was evaluated additionally for measurement of TGF-␤1 in cell culture supernatants. Because in these fluids the protein content varies considerably compared with that of serum or plasma, we investigated the influence of the protein concentration on nonspecific binding of TGF-␤ to the assay plates [24] . A BSA concentration of at least 1 g/L is sufficient to prevent nonspecific adsorption of rhTGF-␤1 (recovery Ͼ90%), whereas in protein-free DMEM Ͼ50% of added TGF-␤ is lost. Further increasing the BSA concentration up to 20 g/L did not improve the results.
method comparison
Regression analysis. For assay comparison, aliquots of frozen serum (n ϭ 16) and plasma samples (n ϭ 5 to 15) were thawed and measured with 2 or 3 assay kits in parallel. The recommendations of the respective manufacturers were strictly followed. For the comparison method, we generally used our newly developed in-house assay. Therefore, the results of a regression analysis according to the robust method of Passing and Bablok are given pairwise in relation to the in-house assay (Table 1) . Aliquots of a serum pool (ϳ45 g/L TGF-␤1) were used for assessment of the within-series and interassay CVs.
The Promega immunoassay generally measured much higher concentrations of TGF-␤1 in serum or plasma samples than did the other assays. Additionally, these concentrations did not show any correlation to those obtained by the other kits. The differences could not, however, be attributed to a different calibration because our TGF-␤1 preparation gave nearly identical results by both the Promega and the in-house assay. We did not further investigate the reason for these differences, but the most probable explanation might be that, when assaying blood samples, the Promega assay is strongly influenced by interfering substances not identical with TGF-␤1.
Imprecision. Except for the Promega assay, the intermethod comparability of the other assays shown in Table  1 was satisfactory. Although the correlation coefficients were generally acceptable (0.71-0.95), the linear regression slopes nevertheless ranged between 1.83 for the Predicta assay and 0.89 for the Amersham assay. These discrepancies can be explained at least in part by the use of different calibrators; different activation procedures and different susceptibility of the assays to matrix effects also will lead to variations. The analytical imprecision, i.e., within-run and within-series CVs, of the assays investigated were acceptable for immunoassays. Because the Amersham assay was performed only twice, we estimated its within-series CV by computing the median value of the CV obtained from 16 serum samples measured in duplicate.
Detection limit and TGF-␤1 determination in nonactivated samples. The detection limits of all assays are sufficient to allow determination of TGF-␤1 in serum or plasma. However, for determinations in other biological samples, e.g., cell culture supernatants, a lower detection limit is advantageous. The in-house assay and the Quantikine assay had the lowest detection limits, 1.9 and 3.9 ng/L, respectively. That of both the Predicta and the Amersham assay was ϳ10 times higher. In nonactivated plasma (sodium citrate or EDTA as anticoagulant) or serum samples, all assays reported TGF-␤1 concentrations well Ͻ100 ng/L or did not detect any.
These results differ from those of Grainger et al. [16] , who described two assay variants specific for active and (active ϩ latent) TGF-␤1 but with the samples needing no acidification. They reported fractions of active/(active ϩ latent) TGF-␤1 between Ͻ0.1 and 1 in serum or plasma samples. At present we have no explanation for these discrepancies but it should be noted that the concentration range found by Grainger et al. for (active ϩ latent) TGF-␤1 in serum (Ͻ0.1-35 g/L) is considerably less than the ranges found by any other assay tested (see Table 2 ). These differences are most probably the result of using different methodologies because the assays described by Grainger et al. operate (a) without acid activation and (b) do not detect the large latent complex released from platelets, whereas the assays we tested generally measure total TGF-␤1 after activation.
Cross-reactivity with isoforms TGF-␤2 and TGF-␤3.
The cross-reactivity for the TGF-␤ isoforms 1 and 2 was tested by measuring recombinant TGF-␤2 and TGF-␤3 at concentrations of 100 g/L in the diluent provided by the respective manufacturers. In all assays compared, the cross-reactivity was negligible for all practical purposes, being below or near the detection limit.
Effects of sample dilution. Deviations from linearity were noticed when human plasma or serum samples were diluted. This problem has been described many times in the literature and has been attributed to "matrix effects," the nature of which, to our knowledge, was never analyzed in detail. To circumvent these effects from producing "bizarre dilution curves," some authors advocate an obligatory acid-ethanol extraction of biological samples [20] .
To further investigate this phenomenon, we prepared serial dilutions of identical serum samples, which we measured with the four commercial TGF-␤1 assays and the in-house assay. According to the manufacturers' recommendations, the samples were prediluted 30-to 60-fold (except for the Promega assay, which required a 120-fold starting dilution) to obtain a starting concentration at the upper end of the measuring range of the respective assay. Then, the samples were further diluted Fig. 2 , all assays displayed nonlinearity, with the Promega assay performing worst, giving variations of the apparent TGF-␤1 concentrations of Ͼ2.5-fold, depending on the extent of dilution. Only the Quantikine and in-house assays (the latter with activation procedure 2) gave consistent results that were largely independent of the extent of dilution.
The most obvious difference between the Quantikine and in-house assays and the remaining assays is the activation procedures used. Therefore, we tested whether an activation procedure similar to those of the other assays led to dilutional nonlinearity. Indeed, using activation procedure 1 (see Materials and Methods) with both the Quantikine assay and the in-house assay gave nonlinear dilution curves similar to those of the other assays (Fig. 2) .
Nonspecific matrix effects caused by (e.g.) different protein concentrations of sample and diluent are an unlikely cause for the behavior described. In this case one would expect that, in highly diluted samples, differences between sample and calibrator matrices would have been leveled out and lead to linear responses. However, even dilutions of several hundredfold are not sufficient to abolish the nonlinearity. Therefore, other factors must be responsible.
The dilution effects shown above will be even more adverse under routine conditions, given the substantial dilution of the sample required by all assays. Methods with strong dilution bias cannot, therefore, be used reliably to measure TGF-␤1 in blood.
Effects of LAP, ␣2M, and fibronectin on TGF-␤1 measurement.
To test the hypothesis that the dilutional nonlinearity is caused by reassociation of TGF-␤1 with specific binding proteins that compete with the solid-phase antibody of the assays after the activation procedure, we assessed the use of LAP, ␣2M, and fibronectin as model substances.
For the experiments described below we used an earlier variant of the in-house assay, which used a different streptavidin-peroxidase concentration that extended the calibration curve to an upper limit of 2 g/L (80 pmol/L). All other properties of this assay were identical to the in-house assay described above.
Various concentrations of rhLAP , ␣2M, or fibronectin were mixed with rhTGF-␤1 (40 pmol/L) in assay buffer to yield different proportions of the concentrations of the respective molecules. For ␣2M, the highest concentration used corresponded to the upper limit of the reference range for adults (3 g/L) [25] . After incubation at room temperature for 1 h, the TGF-␤1 concentration was measured by the in-house assay with overnight sample incubation. As Fig. 3 shows, under the conditions described, rhLAP and ␣2M but not fibronectin are able to nearly completely mask TGF-␤1. The suppression caused by rhLAP and ␣2M was reversible; i.e., after transient acidification, the expected amount of TGF-␤1 was largely recovered (data not shown).
To further investigate the nonlinearity of the dilution curves in a different model system, we diluted rhLTGF-␤1 (40 nmol/L) in assay buffer and subjected it to acid activation according to procedure 1. After neutralization and twofold serial dilution, the samples were measured with the in-house assay. rhTGF-␤1 served as the control, being treated and measured in parallel. As shown in Fig.  4 , this simple system gives results comparable with those obtained for the complex serum/plasma samples shown in Fig. 2 .
model computations
Numerous proteins are known to form strong noncovalent associations with TGF-␤1. For the sake of simplicity, our model system contained only ␣2M and LAP as major The effects of different sample activation procedures were demonstrated by using the in-house assay. In in-house procedure 1 (conventional activation) sample dilution follows neutralization, whereas in in-house procedure 2 (optimized activation) the acidified sample is diluted and neutralized immediately before addition to the microwells.
binding partners for TGF-␤. The following reactions were considered:
We assume that the total concentrations of LAP (M r ϭ 75 000) and TGF-␤ (M r ϭ 25 000) are identical and equal to the mean concentration of latent TGF-␤ found in citrated plasma, i.e., 4 g/L. The total concentration of ␣2M (M r ϭ 725 000) is derived from its mean serum concentration of 2 g/L. We ideally assume that no other binding partners for ␣2M exist besides TGF-␤1. The dissociation constants K 1 and K 2 are values published previously as 10 Ϫ9 and 10 Ϫ7 mol/L, respectively [5, 26] . For simulation of the immunoassay situation, we introduce a reaction between TGF-␤1 and an antibody Ab, which for simplicity we assume are equimolar:
The dissociation constants K 3 of the Ab binding to TGF-␤ are varied between 10 Ϫ9 (relatively low affinity) and 10 Ϫ11 mol/L (high affinity). We further assume that the signal finally obtained by the immunoassay procedure is proportional to the concentration of the species Ab-TGF-␤, i.e., the amount of TGF-␤ bound by the solidphase antibody. The total concentration of the antibody is estimated from the situation found for the coated microwell. We approximate the volume concentration by the amount of antibody bound to the plastic surface. If the saturating surface concentration is taken as 100 ng/cm 2 , the upper limit for the antibody concentration in conventional microwells corresponds to ϳ1 mg/L [27] .
For the above system with an assumed antibody affinity (K 3 ) of 10 Ϫ9 mol/L, we obtained the following equilibrium concentrations:
In this system the most prominent fraction of TGF-␤ is bound to ␣2M; very minor amounts are bound to LAP, and 4.7 pmol (2.9%) is present as free TGF-␤.
Next, we simulated the effect of sample dilution by serially diminishing the total concentrations of all components except for the concentration of the antibody. The latter concentration remains constant because the antibody is immobilized at the surface of the microwells. The concentrations of Ab-TGF-␤ obtained at various dilutions were compared with those of an identically diluted simple calibrator solution that contained Ab and TGF-␤ only. For better comparability, we normalized the dilution curves by dividing all values by the concentration of the most concentrated solution.
The resulting curves for different antibody affinities ( Fig. 5) are strikingly similar to the dilution curves obtained experimentally by the assays we evaluated. According to the simulation, the different susceptibilities of the assays to sample dilution are strongly dependent on the affinity of the respective solid-phase anti-TGF-␤ antibody. This conforms with the influence of dilution being only marginal for the Quantikine assay (Fig. 2) , because this assay uses the high-affinity type II TGF-␤ receptor [28] (K D ϭ 5-50 pmol/L) as the solid-phase capture agent. However, an additional effect of the special activation procedure of the Quantikine assay, which uses acidified 10 mol/L urea, might also play a role. Perhaps reassociation between TGF-␤ and its binding partners is suppressed by the urea concentration remaining after neutralization (ϳ0.3 mol/L) or maybe the binding proteins are degraded in the presence of 10 mol/L urea.
In human blood samples ␣2M presumably is most important in binding to TGF-␤, but other proteins with similar or higher affinities, such as proteoglycans [3, 4] , might also be effective. ␣2M also binds numerous other proteins, e.g., cytokines, and might therefore not be fully available for binding TGF-␤. However, because in the system described above only a very small fraction (Ͻ0.00005) of total ␣2M was saturated by binding TGF-␤, the competition between TGF-␤ and other proteins for ␣2M is probably not important. We stress, however, that the simulation results have been derived by assuming a reversible equilibrated system. Because kinetic effects are completely ignored by this simulation model, we also performed some experiments on the kinetics of reassociation.
kinetics of reassociation
The aim of the following experiments was to determine the influence of the time lag between neutralization of samples and start of exposure to the solid-phase antibody. The in-house assay was used for these experiments. Serum samples were diluted 1:50, 1:100, 1:200, 1:400, and 1:800 in assay buffer. The samples were activated by mixing 2000 L of sample with 200 L of 1 mol/L HCl for 15 min at room temperature and were neutralized by addition of 200 L of 1 mol/L NaOH. The first aliquot was transferred to the microwells immediately after neutralization; subsequent aliquots were transferred after 5, 10, 30, and 120 min. As a control, one aliquot was left acidified for 120 min and neutralized only afterwards. To assess the possibility of losses from adsorption to the walls of the sample tubes, we transferred this aliquot to a fresh tube before neutralization. Every row of 12 wells underwent the usual washing procedure immediately before addition of the samples, to prevent the microwells from drying out when standing for a prolonged time after washing. The sample incubation was continued overnight for 18 h and the assay was performed as usual.
The apparent concentration of TGF-␤1 steadily declined with incubation time after neutralization (Fig. 6 ). This effect was statistically significant (one-way ANOVA, multiple range tests) for the concentrations measured 30 and 120 min after neutralization and also confirms the assumption of a partial reassociation of TGF-␤1 and its binding partners as a cause for the dilutional nonlinearity. Although the concentration of the control was lower than the concentration of the sample measured immediately after neutralization (0 min), this difference was not statistically significant. A slight degradation of TGF-␤1 during the 120 min of acidification might be responsible for the lower concentration of the control. In a similar experiment we investigated the reassociation kinetics of the activation procedure used by the Quantikine assay, i.e., activation with 2.5 mol/L acetic acid/10 mol/L urea for 10 min followed by neutralization with 2.7 mol/L NaOH in 1 mol/L HEPES. The time-dependent decrease in the apparent concentration of TGF-␤1 found with this procedure was less pronounced than in the HCl/NaOH procedure. The acetic acid/urea activation is not completely irreversible, however; 120 min after neutralization the fraction of TGF-␤1 found was 0.8 compared with the 0.68 found with the HCl/NaOH procedure (Fig. 6) . Activation with 2.5 mol/L acetic acid/10 mol/L urea might therefore A sample that had been acidified for 120 min was neutralized just before addition to the microwells to serve as a control.
be an acceptable alternative when our recommended neutralization procedure is not feasible.
comparison between serum and plasma samples TGF-␤1 was measured in serum or plasma samples from patients submitted for routine analysis in our laboratory. TGF-␤1 was activated and the samples were measured as described. The median concentrations obtained with the four commercial assays and the in-house assay, compiled in Table 2 , show that all assays measure clearly higher concentrations in serum than in plasma. Although the serum and plasma samples compared were not obtained from identical patients, the ratio of the median serum/ plasma concentrations was nonetheless similar for all assays compared. Because ␣-granula of platelets contain TGF-␤1 in high concentrations [29] , the fact that serum concentrations are relatively greater than in plasma is most likely caused by platelet degranulation during the clotting process [20] . This explanation is supported further by the strong positive correlation between platelet count and the serum concentration of TGF-␤1; correlations between platelet count and TGF-␤1 concentrations in citrated plasma were generally not significant (Table 2) . Only the Promega assay markedly differed from the other assays, yielding a negative correlation between platelet count and TGF-␤1 serum concentration as well as a clearly lower TGF-␤1 serum/plasma ratio.
concluding remarks
There has been much controversy concerning the immunological determination of TGF-␤ in biological samples. The main problems discussed were (a) the nonparallelism between calibration curves and sample dilution curves, (b) the suitability of different kinds of samples (serum vs plasma anticoagulated with citrate or EDTA), and (c) the influence of preanalytical factors.
We were able to explain the nonlinearity of sample dilution curves, which is often attributed to unspecific matrix effects, by assuming a simple competitive binding model. Theoretical considerations indicated that the dilution linearity mainly depends on the affinity between solid-phase reactants and TGF-␤. This comfortably explains the differences in dilution linearity in the assays compared. This model is based on the assumption of at least a partial reassociation between TGF-␤ and its binding partners after neutralization. However, as the system is obviously far from having reached its equilibrium state immediately after neutralization, reassociation kinetics must be considered in addition. Both assumptions combined provide the rationale for an appropriately redesigned activation/neutralization procedure that avoids dilutional nonlinearity. Therefore, direct measurement of total TGF-␤ in blood becomes possible without resorting to acid-ethanol extraction procedures, which activate latent TGF-␤1. Use of the latter procedures renders measurement of active TGF-␤ in blood generally not possible. These time-and labor-consuming extraction procedures depend on the reliability of the assessment of the overall recovery of TGF-␤. Because in vivo TGF-␤ might occur associated to various binding partners in variable amounts, it seems doubtful whether the simple use of 125 I-labeled TGF-␤ for assessment of recovery is sufficient. Furthermore, the different kinetics of naturally occurring (i.e., latent) TGF-␤ and free (labeled) TGF-␤ will influence the extraction efficacy. Measurement of native (biologically active) TGF-␤ can be performed by omitting the activation step and preferably by using an assay that is based on receptor binding. However, the amount of TGF-␤ that is available for binding to the receptor will depend in a nonlinear way on the composition of the system of binding proteins, receptor, and TGF-␤, i.e., on sample dilution. For a realistic approximation of biologically active TGF-␤, undiluted samples are therefore preferred.
The assays tested should not be used to measure TGF-␤ concentration in serum samples. The highly significant correlation to platelet counts strongly indicates that a major part of the TGF-␤ detected in serum is released from platelets during the clotting process. Therefore, investigations focused on determining the diagnostic value of circulating TGF-␤ in serum should be viewed critically. This topic has been addressed extensively by Wakefield et al. [20] , who recommend measurement of TGF-␤ in plasma and subsequent correction for platelet degranulation via measurement of platelet factor 4.
␣2M and possibly several other binding proteins might play a specific physiological role as scavengers for a whole range of various cytokines in addition to TGF-␤. Therefore, we assume that the effects presented here should be considered as having general importance for immunoassay design.
